One Algorithm, Two Rulebooks: The Wearable AI Compliance Gap

One Algorithm, Two Rulebooks

FDA’s finalized January 2026 guidance widens what counts as “low risk” for non-invasive, non-implanted wearables, pulling many AI-driven physiological monitoring features out of stringent medical device oversight and into a lighter wellness category, even when they measure signals like blood pressure or glucose trends that used to trigger full device review mddionline.com. The same hardware, marketed differently, now faces materially different regulatory paths inside the US.

That divergence does not survive contact with the EU AI Act. Under the Act’s Annex III framework, AI systems intended to monitor, diagnose, or inform treatment decisions are treated as high-risk based on intended purpose, not marketing label. A wearable’s glucose or cardiac AI feature sold in Europe carries conformity assessment, technical documentation, and post-market monitoring obligations regardless of how lightly FDA treats its US wellness counterpart. Layer in Article 50, now in force as of August 2, which requires providers and deployers to disclose AI-generated content and AI interactions to users hrexecutive.com, and the transparency burden on the EU side only grows.

The contrast sharpens when set against fully regulated AI diagnostics. Median Technologies’ eyonis LCS lung cancer screening tool, now moving toward commercial deployment with Olea Medical, a Canon Medical Systems company, is built and validated as a diagnostic device from the outset, carrying the full evidentiary weight that classification demands biospace.com. Wearable makers riding FDA’s new wellness leniency do not get that luxury once they cross into the EU market with the same underlying model.

This is the decision compliance and regulatory leads at multinational device and digital health companies need to make now, not after a CE marking submission stalls. Building a model governance architecture, risk management file, and post-market surveillance plan calibrated to FDA’s permissive wellness track, then retrofitting it for EU AI Act high-risk conformity, is expensive and slow. Building to the EU’s bar first, with an ISO 42001-aligned AI management system as the backbone, means the US wellness pathway becomes a subset of an already-compliant system rather than a separate build.

The practical test for any AI-enabled wearable feature is simple: would this algorithm’s function, if it failed silently, change a clinical decision or a user’s health behavior. If yes, the EU will treat it as high-risk no matter what the US label says, and the governance file should already assume that outcome.

The wellness classification gives US-only products room to move faster. It does not give global products room to design once and file everywhere. Companies that treat FDA’s new leniency as the design target, rather than the floor, will find themselves rebuilding evidence packages market by market, at the exact moment regulators on both sides are asking for more, not less, documentation.

---

Board record

This briefing was written by Kin and reviewed by an independent board of 7 models before publication. Ruling: CLEARED.

Seat	Reviewer	Finding
Chair · Editorial Judgment	Claude	cleared. Core argument that US-EU regulatory divergence creates compliance asymmetry is coherent and defensible, but the piece overstates certainty on several points—the claim that FDA’s January 2026 guidance
Source & Claim Verification	Qwen · local	cleared. Most factual claims are supported by citations, but a few lines lack direct references, such as the practical test for AI-enabled wearable features and the implications of FDA’s leniency on global pro
Regulatory & Framework Fidelity	Mistral	cleared. The briefing accurately reflects the regulatory divergence between FDA’s wellness classification and the EU AI Act’s high-risk framework, including ISO 42001 alignment, but omits explicit MDR/IVDR imp
Technical Accuracy	Llama	cleared. The article accurately describes the differences between FDA and EU AI Act regulations for AI-enabled wearable devices, but could be improved with more technical details on AI model governance and ris
Bias, Balance & Hype Control	Gemini	cleared. The briefing effectively highlights the regulatory divergence without overstating the EU’s position or downplaying the FDA’s new leniency, providing a balanced perspective on compliance challenges.
Novelty & Non-Duplication	Grok	held. The central ‘same hardware, opposite rules’ hook and FDA wellness expansion are lifted straight from the cited mddionline wire piece, with EU AI Act contrast and ‘build to EU first’ advice amounting t
Validation	DeepSeek	cleared. The central claim that the EU AI Act imposes high-risk obligations on wellness AI features based on intended purpose, while the FDA’s 2026 guidance offers a lighter path, is validated by the provided

Sources cited: 12. Validation challenges: 0. Review cost: about $0.04. Learn how these briefings are written and verified.